• Opinion
• [Reporter’s View] LG Chem’s global two-track strategy
• by Oct 20, 2022 06:02am

• Opinion
• [Desktop] Increase accessibility by beating generic prices
• by Kim, Jung-Ju Oct 19, 2022 05:48am

• Opinion
• [Reporter’s View] The key to the ‘PE Exemption’ issue
• by Eo, Yun-Ho Oct 17, 2022 10:52pm

• Opinion
• [Reporter’s View] Real crisis will come after COVID-19
• by Kim, Jin-Gu Oct 5, 2022 06:11am

• Opinion
• [Reporter's view] Reimbursement of Zerbaxa
• by Eo, Yun-Ho Oct 4, 2022 06:07am

• Opinion
• [Reporter's view]Bio-Administrative Orders of the USA
• by Kim, Jin-Gu Sep 23, 2022 05:51am

• Opinion
• [Reporter's view] Reform of the innovative system
• by Lee, Jeong-Hwan Sep 19, 2022 05:56am

• Opinion
• [Reporter’s View] Evrysdi awaits reimb review for over 1 yr
• by Eo, Yun-Ho Sep 16, 2022 05:53am

• Opinion
• [Reporter's view] PVA market should be actively reflected
• by Lee, Tak-Sun Sep 13, 2022 05:51am

• Opinion
• [Reporter’s View] Novartis's restructuring path similar
• by Eo, Yun-Ho Aug 31, 2022 05:40am